Paper Details

  1. Home
  2. Paper Details

Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.

Author: AbeMitsuhiro, HirasawaYasutaka, IwasawaShunichiro, KasaiHajime, KawasakiYohei, KoshikawaKen, SakayoriMasashi, TatsumiKoichiro, TeradaJiro, TsushimaKenji, YoshiokaKeiichiro

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

ALK-TKIs are effective treatment for lung cancer with ALK gene rearrangement. However, drug-induced lung injury (DILI) is a serious side effect. This study investigated clinical features and risk factors for DILI caused by ALK-TKIs in clinical practice.
Paper Details　
Original Abstract of the Article :
If anaplastic lymphoma kinase (ALK) gene rearrangement in lung cancer is identified, ALK-tyrosine kinase inhibitors (ALK-TKIs) can be an effective treatment. However, the details of drug-induced lung injury (DILI) caused by ALK-TKI, which can be a serious side effect of ALK-TKIs, remains unclear. Th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262910/

データ提供：米国国立医学図書館（NLM）

Drug-Induced Lung Injury: A Growing Concern

Targeted therapies have revolutionized cancer treatment, offering hope for patients with difficult-to-treat conditions. However, the use of these targeted therapies is not without risk. One potential concern is drug-induced lung injury (DILI), a serious side effect that can significantly impact a patient's health. This study delves into the clinical features and risk factors associated with DILI specifically caused by ALK-tyrosine kinase inhibitors (ALK-TKIs), a class of drugs used to treat lung cancers with ALK gene rearrangements.

Understanding the Risks of ALK-TKIs

The study's findings highlight the importance of closely monitoring patients receiving ALK-TKIs for signs of DILI. The researchers found that DILI can manifest with a variety of symptoms, including cough, shortness of breath, and fever. They also identified potential risk factors for DILI, including age, smoking history, and prior exposure to other lung-toxic medications. This information is essential for healthcare professionals to tailor their approach to patient care and identify patients who may be at higher risk for DILI.

Staying Vigilant During Treatment

Knowing the potential risks of ALK-TKIs is crucial for patients undergoing treatment. Open communication with your healthcare provider is essential. Be sure to report any new or worsening symptoms, particularly those related to your lungs, so that any potential complications can be addressed promptly. By working together, patients and their healthcare teams can navigate the challenges of cancer treatment while minimizing the risk of DILI.

Dr. Camel's Conclusion

Think of ALK-TKIs as a powerful camel caravan traversing a treacherous desert landscape. While these drugs offer hope for those battling lung cancer, they also carry the potential for unexpected storms like DILI. It's like navigating a sandstorm - staying alert, communicating openly, and being prepared for potential hazards are vital for a successful journey. By working closely with their doctor, patients can navigate this challenging terrain with confidence and emerge victorious.

Date :
  1. Date Completed 2021-03-11
  2. Date Revised 2021-03-11
Further Info :

Pubmed ID

32237210

DOI: Digital Object Identifier

PMC7262910

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.